 |
| Issue 9, 30 June 2007
|
Dear Shareholders
Welcome to the latest edition of Apollo Life, our regular newsletter to keep shareholders informed about our latest developments.
If you would like any further information, please contact us.
Regards
John Priest - CEO |
|
|
 |
Strengthening Apollo's global patent position - Transdermal delivery
Apollo has strengthened the positioning of its transdermal delivery platform with a suite of new patent applications, based on recently completed developments.
The additional patent applications build upon the delivery platform’s “foundation” international (PCT) patent application and cover novel formulations that have the capability of delivering more concentrated amounts of active cosmetic or therapeutic agents into the skin. |
|
|
|
Professor Paul Zimmet wins prestigious Novartis Award
The Chair of Apollo’s Diabetes Advisory Board and member of its Scientific Advisory Panel, Professor Paul Zimmet, has been awarded the 2007 International Novartis Award for his groundbreaking diabetes research and activism.
The award recognises outstanding individuals who have dedicated themselves to improving the lives of people with diabetes. It recognises accomplishments by an individual in clinical research, education, and clinical practice that have had a major impact on the field of diabetes mellitus. |
|
Apollo's human proteins boost stem cell research
Apollo Life Sciences has developed a pivotal, and potentially lucrative, role in the area of stem cell research, leading the world in the production of human proteins for stem cell research.
Apollo's Head of Protein Development, Glenn Pilkington, said the company’s human proteins are unique in the way they help stem cells to develop into specific cell types such as heart, nerve and muscle cells. |
|
Global Media Attention for Apollo’s Stem Cell Proteins
Apollo’s media release on stem cells, timed to coincide with the Cairns ISSCR meeting, led to global attention for Apollo’s human cell expressed proteins.
Having the world’s largest range of human based proteins puts Apollo in the driver’s seat when it comes to delivering the sorts of proteins crucial for the development of stem cell therapies worldwide, according to CEO, Mr John Priest. And the world’s journalists agreed, filing copy for online publications and editorials internationally. |
|
| Click here to subscribe |
 |
| www.apollolifesciences.com |